Stay updated on Vibecotamab in MRD+ AML/MDS Clinical Trial

Sign up to get notified when there's something new on the Vibecotamab in MRD+ AML/MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Vibecotamab in MRD+ AML/MDS Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The value 2023-12-11 has been updated to 2024-05-07 on the webpage, indicating a recent change in the study record related to a Phase II Study of Vibecotamab (XmAb14045) for MRD-Positive AML and MDS after hypomethylating agent failure, possibly in the medical and healthcare field.
    Difference
    1.0%
    Check dated 2024-05-07T20:31:13.000Z thumbnail image
  7. Check
    18 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T23:19:50.000Z thumbnail image

Stay in the know with updates to Vibecotamab in MRD+ AML/MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Vibecotamab in MRD+ AML/MDS Clinical Trial page.